CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report is the form of presentation that Cellular Biomedicine Group, Inc. (the “Company”) used in connection with the Company’s presentation on March 16, 2018 at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium conference in Hangzhou, China, at which the Company presented 48-week clinical data from its Phase I clinical trial in China for allogeneic adipose-derived mesenchymal progenitor cell off-the-shelf therapy Allojoin™ for Knee Osteoarthritis.
On March 16, 2018, the Company issued a press release announcing the presentation of the Allojoin™ Phase I 48-week data in China, as well as the termination of the Company’s U.S. Allojoin™ program with the California Institute of Regenerative Medicine (“CIRM”). Prior to termination, the Company had received $1.2 million of the potential $2.29 million available under the CIRM grant. The press release is attached hereto as Exhibit 99.2.
The foregoing (including Exhibits 99.1 and 99.2) is being furnished to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Presentation, dated March 16, 2018
99.2 Press Release, dated March 16, 2018
Cellular Biomedicine Group, Inc. ExhibitEX-99.1 2 cbmg_ex991.htm PRESENTATION,…To view the full exhibit click here
About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
